Camrelizumab
IRB-2021-389
Phase 3 small_molecule active
Quick answer
Camrelizumab for Esophageal Cancer is a Phase 3 program (small_molecule) at First Tracks Biotherapeutics with 2 ClinicalTrials.gov record(s).
Program details
- Company
- First Tracks Biotherapeutics
- Indication
- Esophageal Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active